Phagenesis wins CE mark for Phagenyx® to treat dysphagia

Manchester, UK – 16th October 2012 -–Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that its treatment system Phagenyx®, the world’s first treatment for acute dysphagia following stroke, has been awarded a CE Mark.

Dysphagia, the inability to swallow safely, is a debilitating condition that affects about half of all stroke patients. Dysphagia frequently leads to potentially life-threatening pneumonia and the surgical implantation of a PEG tube to allow a patient to be fed indefinitely through the abdomen wall.

The CE Mark paves the way for Phagenyx® to be launched in Europe, where there are more than 1 million strokes per year.

The Phagenyx® treatment system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. This protocol has shown to lead to a clinically and statistically significant improvement in swallowing function in a majority of dysphagia patients. Phagenyx® is the result of almost 20 years of research and development, led by Professor Shaheen Hamdy of the Salford Royal Hospital and the University of Manchester.

Daniel Green, CEO of Phagenesis, said: “The Phagenyx® treatment system allows doctors, nurses and speech and language therapists to alleviate the suffering of hundreds of thousands of stroke patients across the world. The CE marking will allow the system to be rolled out across Europe and other territories.”